Drug Profile
Research programme: antimicrobial biotherapeutics - Eligo Bioscience
Alternative Names: Eligobiotics; Sequence-specific antimicrobialsLatest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Eligo Bioscience
- Class Antibacterials; Gene therapies
- Mechanism of Action Gastrointestinal microbiome modulators; Gene modulators; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Bacterial-infections in France
- 02 Dec 2019 Research programme: antimicrobial biotherapeutics - Eligo Bioscience is available for licensing as of 02 Dec 2019. https://eligo.bio/collaborate/
- 17 Sep 2019 Preclinical development of the antimicrobial biotherapeutics is ongoing in France